Orion Corporation acquires Inovets veterinary business

Orion Corporation (Orion), a Finnish pharmaceutical company, has entered into an agreement with the private Belgian company Inovet BV (Inovet), for the acquisition of its wholly owned subsidiary VMD NV and all companies belonging to the VMD NV group. VMD is a veterinary pharmaceutical company specializing in medicines and health products for farm animals. It also has products for companion and other animals. VMD is headquartered in Arendonk, Belgium. VMD has production facilities in Arques (manufacturing) and Arendonk (packaging) in France, as well as its own sales operations in Belgium, France, Hungary and Vietnam. VMD's turnover in 2021 was EUR 61 million, and the company made a profit. As a result of the transaction, 181 VMD employees will be transferred to the Orion Group. Through the acquisition, Orion's Veterinary Medicines unit will expand its product offering and gain a foothold in the production animal market, expand its geographical presence in Western Europe and the export market, and acquire a production facility specializing in the manufacture of veterinary medicines. In addition, the acquisition supports the Orion Group's growth strategy. The debt-free purchase price is approximately EUR 130 million. The transaction will be financed from Orion's cash resources. The immediate cash flow effect is approximately EUR 90 million. The transaction will have a positive effect on the net sales and EBITDA of Orion's Veterinary Medicines unit from 2022 onwards. The impact on the Orion Group's net sales and earnings is not material, and the acquisition will not affect Orion's February 2022 outlook for the full year 2022. Orion will report VMD's net sales as part of the Veterinary Medicines unit's net sales as of June 2022. The agreement was signed and the transaction was completed simultaneously today, June 15, 2022.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!